BURLINGTON, Mass., Oct. 12 /PRNewswire/ — InfraReDx,
Inc., a medical device company developing intelligent
cardiovascular diagnostic imaging technologies, today announced the
completion of a $21 million equity financing. This round of
investment attracted new institutions as well as existing
investors, including Sanderling Ventures. Funds from the financing
are being used to support the full commercial launch of the
LipiScan™ IVUS Coronary Imaging System, the world’s first and
only intravascular imaging system that combines and co-registers
grayscale intravascular ultrasound (IVUS) with InfraReDx’s
proprietary near infrared (NIR) spectroscopy lipid core plaque
(LCP) detection technology.
“We are pleased to provide this novel diagnostic tool for the
care of coronary patients. Our existing investors have been very
supportive of the effort to develop LipiScan IVUS and the unique
capabilities of the system have been instrumental in attracting the
support of new investors, as well,” said James E. Muller, M.D.,
founder and chief executive officer of InfraReDx. “The LipiScan
IVUS system will enable interventional cardiologists to accurately
and rapidly identify the lipid core plaques that complicate
stenting and are believed to be the major cause of heart attacks.
Our full commercial launch will bring this important and eagerly
awaited interventional imaging technology to leading
catheterization labs in the U.S. this year. It will be available in
Europe in 2011.”
The LipiScan IVUS system employs proprietary optical imaging
technology to overcome the challenges of heart motion, blood
interference, and vascular access to perform NIR spectroscopic
analysis of the vessel and produce a chemical map of lipid-core
plaque called a Chemogram™. The system provides physicians
with a traditional IVUS image that shows plaque location, degree of
stenosis and degree of stent expansion. At the same time optical
data are
‘/>”/>
SOURCE